The Impact of Supplementation With Novel Prototype Nutrition Bar on Nitric Oxide Bioavailability and Measures of Athlete Performance
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03686982 |
|
Recruitment Status :
Completed
First Posted : September 27, 2018
Last Update Posted : September 27, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Exercise Performance | Other: Active Nitrate Bar Other: Placebo Bar | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 24 participants |
| Allocation: | Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Basic Science |
| Official Title: | The Impact of Supplementation With Novel Prototype Nutrition Bar on Nitric Oxide Bioavailability and Measures of Athlete Performance |
| Actual Study Start Date : | May 1, 2017 |
| Actual Primary Completion Date : | April 15, 2018 |
| Actual Study Completion Date : | April 30, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Active Nitrate Bar
include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
|
Other: Active Nitrate Bar
Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione |
|
Placebo Comparator: Placebo Bar
Containing no active ingredients
|
Other: Placebo Bar
No active ingredients |
- Mean power output during intermittent exercise test [ Time Frame: 5 days of intervention ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male and female participants in self-reported good general health as assessed by the standard procedures described below and specifically meeting the following blood pressure (BP) and body mass index (BMI) ranges: systolic BP: 100-140 mmHg; diastolic BP: 60-90 mmHg; and BMI 18.5-30.
- 18-40 years of age
- Physically active. Determined by meeting the following criteria: completes vigorous physical activity (i.e. activities that take hard physical effort and make you breathe much harder than normal; e.g. heavy lifting, digging, aerobics, fast cycling, running etc) at least 2 x per week and moderate physical activities (i.e. activities that take moderate physical effort and make you breath somewhat harder than normal; for example: carrying light loads, cycling at a regular pace, playing doubles tennis) at least 3 x per week.
- Understanding of the procedures to be undertaken as part of the study
- Willingness to participate in exercise testing and follow supplementation guidelines and other instructions provided by the experimenter
- Informed, voluntary, written consent to participate in the study
Exclusion Criteria:
- Known pulmonary, cardiovascular or metabolic disease
- Food allergies including phenylketonurea (PKU)
- Current regular use of any dietary supplement (excluding macronutrient based supplements) or previous use of any dietary supplement in the past 6 months that is known to have a lasting effect.
- Blood donation within 3 months prior to the start of the study
- Substance abuse within 2 years of the start of the study
- Smoking
- Any prescription and non-prescription medication which may impact saliva production (antidepressants, diuretics, analgesics, antihistamines, anti-hyper/hypo-tensives, anti-anxiety, appetite suppressants).
- Current or previous use of phosphodiesterase 5 (PDE5) inhibitors.
- Participation in another clinical trial within past 4 weeks.
- Participation in another PepsiCo study within the past 6 months.
- Highly trained or elite endurance athlete as determined by current or recent (within 3 months) participation in an endurance sport at international or national level.
- Pregnancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03686982
| United Kingdom | |
| University of Exeter, Sport and Health Sciences department, | |
| Exeter, United Kingdom | |
| Principal Investigator: | Andy Jones, PhD | University of Exeter, Sport and Health Sciences department |
| Responsible Party: | PepsiCo Global R&D |
| ClinicalTrials.gov Identifier: | NCT03686982 |
| Other Study ID Numbers: |
PEP-1706 |
| First Posted: | September 27, 2018 Key Record Dates |
| Last Update Posted: | September 27, 2018 |
| Last Verified: | September 2018 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |

